VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis

Jiahuan Chen, Yi Fu, Daniel S. Day, Ye Sun, Shiyan Wang, Xiaodong Liang, Fei Gu, Fang Zhang, Sean M. Stevens, Pingzhu Zhou, Kai Li, Yan Zhang, Ruei‐Zeng Lin, Lois E. H. Smith, Jin Zhang, Kun Sun, Juan M. Melero‐Martin, Ze‐Guang Han, Peter J. Park, Bing Zhang, William T. PuNature Communications 2017 · DOI

Abstract

Release of promoter-proximally paused RNA polymerase II (RNAPII) is a recently recognized transcriptional regulatory checkpoint. The biological roles of RNAPII pause release and the mechanisms by which extracellular signals control it are incompletely understood. Here we show that VEGF stimulates RNAPII pause release by stimulating acetylation of ETS1, a master endothelial cell transcriptional regulator. In endothelial cells, ETS1 binds transcribed gene promoters and stimulates their expression by broadly increasing RNAPII pause release. VEGF enhances ETS1 chromatin occupancy and increases ETS1 acetylation, enhancing its binding to BRD4, which recruits the pause release machinery and increases RNAPII pause release. Endothelial cell angiogenic responses in vitro and in vivo require ETS1-mediated transduction of VEGF signaling to release paused RNAPII. Our results define an angiogenic pathway in which VEGF enhances ETS1-BRD4 interaction to broadly promote RNAPII pause release and drive angiogenesis.

Introduction

Angiogenesis, the formation of new blood vessels from pre-existing ones, is a critical physiological process in development and a hallmark of various pathologies, including cancer and retinopathy. Vascular Endothelial Growth Factor (VEGF) is the primary signaling molecule driving this process. While the signaling pathways downstream of VEGF receptors are well-characterized, the nuclear mechanisms that translate these signals into coordinated gene expression programs have remained less clear.

Recent research has highlighted Promoter-Proximal Pausing of RNA Polymerase II (RNAPII) as a key regulatory checkpoint. In this process, RNAPII initiates transcription but stalls shortly after the start site. Transitioning to productive elongation requires a "pause release" signal. This study investigates how VEGF signaling interfaces with this transcriptional machinery to drive the rapid and massive gene expression changes necessary for angiogenesis.

Methods and Multi-omic Profiling

To investigate the global transcriptional landscape during angiogenesis, the researchers utilized Human Umbilical Vein Endothelial Cells (HUVECs). They performed a comprehensive multi-omic analysis, including:

  • ChIP-seq & RNA-seq: Mapping the genomic occupancy of ETS1, RNAPII, and BRD4, alongside gene expression levels, following VEGF stimulation over a 12-hour timeline (0, 1, 4, and 12 hours).
  • Pausing Index (PI) Analysis: Quantifying the degree of RNAPII stalling at gene promoters.
  • Mass Spectrometry: Identifying post-translational modifications on the ETS1 protein.
Experimental design and global genomic distribution of ETS1 binding in HUVECs.

The initial profiling revealed that ETS1 is a ubiquitous presence at the promoters of active genes in endothelial cells. As shown in the figure above, ETS1 binding is highly enriched at promoters (28%) and introns (34%), correlating strongly with markers of active chromatin (e.g., H3K27ac, H3K4me3) and the presence of RNAPII.

ETS1 as a Global Transcriptional Amplifier

A key finding of this study is that ETS1 does not merely act as a simple on/off switch for specific target genes. Instead, it functions as a global transcriptional amplifier, similar to the oncogene MYC. ETS1 occupancy at promoters correlates positively with both RNAPII recruitment and overall gene expression levels (FPKM). By overexpressing ETS1, the researchers observed a global decrease in the Pausing Index, suggesting that ETS1 facilitates the release of paused RNAPII across the genome, effectively accelerating the transcription of already active genes.

The Molecular Mechanism: Acetylation and BRD4 Recruitment

The study identifies a sophisticated two-step modification process that links VEGF signaling to transcriptional pause release:

  1. Phosphorylation and Acetylation: VEGF stimulation triggers the phosphorylation of ETS1 via the ERK pathway. This phosphorylation recruits the acetyltransferase CBP, which then acetylates ETS1 at two specific residues: K8 and K18.
  2. The BRD4 Bridge: This specific acetylation pattern creates a docking site for BRD4, a scaffold protein that recruits the Positive Transcription Elongation Factor b (P-TEFb) complex. P-TEFb is the primary machinery responsible for releasing paused RNAPII.

This mechanism operates in two phases. An early phase (within 1 hour) involves the modification of ETS1 already bound to DNA to trigger immediate pause release. A later phase (4-12 hours) involves increased total ETS1 binding to sustain the transcriptional response.

Functional and In Vivo Validation

The biological significance of this pathway was validated through several functional assays:

  • In Vitro: Mutating the acetylation sites (K8/18R) on ETS1 created a dominant-negative effect, significantly impairing VEGF-induced endothelial cell migration and tube formation.
  • In Vivo: Using mouse models, the researchers demonstrated that disrupting the ETS1-BRD4 interaction—either pharmacologically with the BRD4 inhibitor JQ1 or through the expression of non-acetylatable ETS1 peptides—markedly reduced both physiological and pathological angiogenesis (e.g., in oxygen-induced retinopathy models).

Discussion

This research defines a novel angiogenic pathway where VEGF promotes global RNAPII pause release through the ETS1-BRD4 axis. By acting as a transcriptional amplifier, ETS1 allows endothelial cells to rapidly and robustly respond to VEGF signals.

Future work may explore the potential synergy between ETS1 and other amplifiers like MYC, which often occupy the same promoters. From a therapeutic perspective, the specificity of the ETS1-BRD4 interaction offers a promising target for treating neovascular diseases. Targeting this specific interaction might provide a more precise alternative to global BRD4 inhibitors, potentially reducing off-target toxicities in the treatment of conditions like wet age-related macular degeneration or solid tumors.

Summary updated

Abstract

Release of promoter-proximally paused RNA polymerase II (RNAPII) is a recently recognized transcriptional regulatory checkpoint. The biological roles of RNAPII pause release and the mechanisms by which extracellular signals control it are incompletely understood. Here we show that VEGF stimulates RNAPII pause release by stimulating acetylation of ETS1, a master endothelial cell transcriptional regulator. In endothelial cells, ETS1 binds transcribed gene promoters and stimulates their expression by broadly increasing RNAPII pause release. <sup>34</sup> VEGF enhances ETS1 chromatin occupancy and increases ETS1 acetylation, enhancing its binding to BRD4, which recruits the pause release machinery and increases RNAPII pause release. Endothelial cell angiogenic responses in vitro and in vivo require ETS1-mediated transduction of VEGF signaling to release paused RNAPII. Our results define an angiogenic pathway in which VEGF enhances ETS1-BRD4 interaction to broadly promote RNAPII pause release and drive angiogenesis.Promoter proximal RNAPII pausing is a rate-limiting transcriptional mechanism. Chen et al. show that this process is essential in angiogenesis by demonstrating that the endothelial master transcription factor ETS1 promotes global RNAPII pause release, and that this process is governed by VEGF.
BibTeX
@inproceedings{chen2017vegf,
  author = {Jiahuan Chen and Yi Fu and Daniel S. Day and Ye Sun and Shiyan Wang and Xiaodong Liang and Fei Gu and Fang Zhang and Sean M. Stevens and Pingzhu Zhou and Kai Li and Yan Zhang and Ruei‐Zeng Lin and Lois E. H. Smith and Jin Zhang and Kun Sun and Juan M. Melero‐Martin and Ze‐Guang Han and Peter J. Park and Bing Zhang and William T. Pu},
  title = {{VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis}},
  booktitle = {Nature Communications},
  year = {2017},
  doi = {10.1038/s41467-017-00405-x},
}
Figure